ABVV next VRML - MUST READ:
ABVV - breast cancer diagnois / treatment patents alone should be worh tens and even hundreds of millon dollars. The potential here is mind-boggling.
ABVV got a huge new patent on Feb 1 2011 !!!!!!!!!
Announces Patent Issuance For Core engineering utilised In Mammastatin Serum Assay Diagnostic check For Breast Cancer
February 1st, 2011 | by admin |
Abviva, Inc. (Abviva) (OTCBB:AVVA), a biomedical organization engaged inside innovation, improvement and commercialization of breast cancer diagnostic and therapeutic purposes of Mammastatin, introduced these days that the usa Patent and Trademark workplace issued a pivotal patent around the core engineering utilised inside organization’s breast cancer diagnostic check, the Mammastatin Serum Assay (MSA). The patent, titled approaches AND COMPOSITION FOR DIAGNOSING BREAST CANCER would be the most current with the patents inside Mammastatin IP portfolio to concern towards the college of Michigan for breast cancer diagnostic and breast cancer therapeutic makes use of. “Abviva would be the unique licensee with the diagnostic makes use of for Mammastatin inside patent portfolio owned by the college of Michigan and licensed to Abviva,” explained Doug Lane, president and chief executive with the organization. “Abviva has the unique solution to license the therapeutic makes use of of Mammastatin from your college of Michigan to build a single or far more breast cancer therapeutic medications.”
The Mammastatin Serum Assay was formulated from your Mammastatin engineering uncovered by scientists in the college of Michigan Cancer middle and initially printed inside journal Science. This new patent signifies the improved relevance with the Mammastatin Serum Assay for early breast cancer detection and additionally strengthens the intellectual house safety with the check.
The MSA is formulated as a straightforward blood check that identifies and measures the total of Mammastatin in females. The MSA is actually a risk-assessment instrument meant to become utilised by physicians, clinics and hospitals to assist inside early detection of breast cancer and as being a broad population primarily based early breast cancer screening check. The MSA was previously studied on females with and with no breast cancer and developed striking final results. inside authentic research 98% with the females who noted certainly not becoming identified with breast cancer or handled for breast cancer had standard or elevated ranges of Mammastatin, as measured by the MSA. far more importantly, 74% with the females inside research who noted becoming identified with breast cancer or becoming handled for breast cancer had no detectable ranges of Mammastatin existing or really very low ranges. These findings correlated together with the authentic homework executed in the college of Michigan Cancer middle that demonstrated Mammastatin was generally developed by breast epithelial cells in healthy and balanced females and was lacking or lowered in transformed breast epithelial cells.
Lane explained Abviva intends to present early entry towards the Mammastatin Serum Assay to females and their physicians, clinics and hospitals later this 12 months.
About Abviva
Abviva, Inc. is actually a biomedical organization engaged inside innovation, improvement and commercialization of breast cancer diagnostic and therapeutic purposes of Mammastatin, a previously mysterious secreted expansion inhibitory protein uncovered in the college of Michigan Cancer middle that demonstrated anti-breast cancer properties. The discovery was formulated into a straightforward breast cancer blood check that demonstrated healthy and balanced females have large or standard ranges with the protein and females with breast cancer don’t have any detectable ranges with the protein or really very low ranges. Abviva intends to commercialize the Mammastatin Serum Assay and present the check as being a homework check offered by its wholly owned subsidiary reference laboratory, Biomedical Diagnostics. Abviva also intends to build a breast cancer remedy that earlier demonstrated marked enhancement of breast cancer in palliative Stage IV breast cancer sufferers that have been handled with an early type with the protein remedy beneath Compassionate Use.
http://www.breastcancerdiagnostic.com
Statements on this press launch that aren’t strictly historical info are “44 – 68? statements (identified by the phrases “19?, “estimate”, “95?, “39? or related expressions) inside of the that means with the personal Securities Litigation Reform Act of 1995. These statements inherently contain hazards and uncertainties that might induce real final results to differ materially from your forward-looking statements. aspects that will induce or contribute to these kinds of variations incorporate, but aren’t constrained to, continued acceptance with the organization’s products and solutions and solutions inside market, aggressive aspects, alterations inside regulatory setting, along with other hazards thorough inside organization’s periodic report filings together with the Securities and trade Commission. The statements on this press launch are created as of these days, primarily based upon info presently regarded to management, and also the organization isn’t going to undertake any obligation to publicly update or revise any forward-looking statements.